Alivus Life Sciences profit and loss

Latest FY24

Revenue: ₹2,283cr+5.6% on FY23
EBITDA: ₹674cr+5.0% on FY23

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022

Expenses
	2,684	2,283	2,161	2,123
	79.0	—	29.0	14.7
	2,763	2,295	2,190	2,138
	1,057	1,059	1,099	1,002
	−12.3	−56.6	−84.4	41.3
	282	258	180	169
	5.4	1.5	0.5	28.0
	82.3	53.5	42.1	37.9
	434	—	325	296
	1,849	1,664	1,562	1,573
	923	674	642	616
	840	621	600	578
Profit
	914	—	—	—
	−25.7	—	—	—
	888	631	629	565
	216	152	151	138
	2.8	8.2	11.0	8.6
	219	160	162	146
	670	471	467	419
	670	—	—	—
	2.4	—	—	—
	672	465	467	419
Per share
	₹54.54	—	₹38.11	₹35.63
	₹54.43	—	₹38.11	₹35.63
Other comprehensive income — detail
	2.4	—	—	—
	3.3	—	—	—
	0.8	—	—	—
Per share — as-filed variants
	₹54.54	—	—	—
	₹54.43	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,639	1,281	1,147	1,080
	61.1%	56.1%	53.1%	50.9%
Adjusted (ex-exceptional items) — derived
	914	—	—	—
	−25.7	—	—	—
	689	—	—	—
	₹56.12	—	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALIVUS₹1,243.00

Alivus Life Sciences Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersDIVISLAB AARTIDRUGS AKUMS AGARWALEYE APLLTD ADVENZYMES AARTIPHARM CORONA

View

In ₹ Crore except Per Share 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	Last 12M 30/09/2026
Revenue from Operations	2,123.2	2,161.2	2,283.2	2,684.4
Other Income	14.7	29.0	—	79.0
Total Income	2,137.9	2,190.2	2,295.3	2,763.4
Expenses
+ Cost of Materials Consumed	1,001.6	1,098.5	1,058.6	1,057.5
+ Changes in Inventories	41.3	-84.4	-56.6	-12.3
+ Employee Benefit Expense	168.7	180.2	258.2	282.3
+ Finance Costs	28.0	0.5	1.5	5.4
+ Depreciation & Amortisation	37.9	42.1	53.5	82.3
+ Other Expenses	295.5	324.7	—	434.2
Total Expenses	1,573.0	1,561.6	1,664.0	1,849.4
EBITDA	616.1	642.3	674.2	922.7
EBIT	578.2	600.2	620.8	840.4
Profit
PBT before Exceptional Items	—	—	—	914.0
+ Exceptional Items	—	—	—	-25.7
Pretax Income	564.9	628.6	631.3	888.4
+ Current Tax	137.6	150.6	152.2	215.9
+ Deferred Tax	8.6	11.0	8.2	2.8
Tax Expense	146.2	161.6	160.4	218.6
Net Income	418.7	467.0	470.9	669.7
+ Net Income — Continuing Ops	—	—	—	669.7
+ Other Comprehensive Income	—	—	—	2.4
Total Comprehensive Income	418.8	466.7	465.4	672.2
Per Share
Basic EPS	35.63	38.11	—	54.54
Diluted EPS	35.63	38.11	—	54.43
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	2.4
+ Items NOT to be Reclassified to P&L	—	—	—	3.3
+ Tax on Items NOT to be Reclassified	—	—	—	0.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	—	—	—	54.54
Diluted EPS — Continuing Operations	—	—	—	54.43
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,080.3	1,147.1	1,281.2	1,639.2
Gross Margin %	50.88	53.08	56.11	61.07
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	—	—	—	914.0
− Exceptional Items (reconciliation)	—	—	—	-25.7
Net Income Adj (tax-effected)	—	—	—	689.1
EPS Adj	—	—	—	56.12
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	—	—	—	2.00
Paid Up Equity Capital	—	—	—	24.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.